Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
400 participants
OBSERVATIONAL
2019-04-11
2022-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Circulating Tumor DNA in Surgical Lung Cancer Patients
NCT03081741
Comparison of Circulating Tumor DNA and Tumor Tissue DNA by Targeted Sequencing in Non-Small Cell Lung Cancer
NCT02645318
Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing
NCT03320044
Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients
NCT03664843
Identify Prognostic Biomarkers of Lung Cancer
NCT05010330
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Circulating tumor DNA(ctDNA) detection has been proved to be feasible in early stage NSCLC in previous studies.Both genomic mutation and methylation a promising biomarker.Therefore,this study will perform multiplex detection of ctDNA,analysing mutations, methylation and other biomarkers,focusing on the early diagnosis and postoperative surveillance for NSCLC patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Found small nodules in pulmonary by CT and prepare for surgery;
Exclusion Criteria
2. Receiving chemotherapy, radiotherapy or targeted therapy before surgery;
3. No matching tissue or blood samplesUnqualified blood samples
4. Lesion is pure ground glass opacity.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jun Wang
Chief，Thoracic Surgery Service
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kezhong Chen, MD
Role: STUDY_DIRECTOR
Peking University People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PTHO1701
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.